161 related articles for article (PubMed ID: 36282272)
1. Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma.
Haertle L; Barrio S; Munawar U; Han S; Zhou X; Simicek M; Vogt C; Truger M; Fernandez RA; Steinhardt M; Weingart J; Snaurova R; Nerreter S; Teufel E; Garitano-Trojaola A; Da Viá M; Ruiz-Heredia Y; Rosenwald A; Bolli N; Hajek R; Raab P; Raab MS; Weinhold N; Haferlach C; Haaf T; Martinez-Lopez J; Einsele H; Rasche L; Kortüm KM
Clin Cancer Res; 2023 Jan; 29(1):279-288. PubMed ID: 36282272
[TBL] [Abstract][Full Text] [Related]
2. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
3. A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax.
Downey-Kopyscinski SL; Srinivasa S; Kisselev AF
Sci Rep; 2022 Jul; 12(1):12788. PubMed ID: 35896610
[TBL] [Abstract][Full Text] [Related]
4. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
Zhu YX; Tiedemann R; Shi CX; Yin H; Schmidt JE; Bruins LA; Keats JJ; Braggio E; Sereduk C; Mousses S; Stewart AK
Blood; 2011 Apr; 117(14):3847-57. PubMed ID: 21289309
[TBL] [Abstract][Full Text] [Related]
5. ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.
Yang Y; Gao Y; Huang J; Yang Z; Luo H; Wang F; Xu J; Cui Y; Ding H; Lin Z; Zhai X; Qu Y; Zhang L; Liu T; Ye L; Niu T; Zheng Y
JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36040812
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma.
Allmeroth K; Horn M; Kroef V; Miethe S; Müller RU; Denzel MS
Leukemia; 2021 Mar; 35(3):887-892. PubMed ID: 32690882
[No Abstract] [Full Text] [Related]
7. Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
Lichter DI; Danaee H; Pickard MD; Tayber O; Sintchak M; Shi H; Richardson PG; Cavenagh J; Bladé J; Façon T; Niesvizky R; Alsina M; Dalton W; Sonneveld P; Lonial S; van de Velde H; Ricci D; Esseltine DL; Trepicchio WL; Mulligan G; Anderson KC
Blood; 2012 Nov; 120(23):4513-6. PubMed ID: 23018640
[TBL] [Abstract][Full Text] [Related]
8. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
[TBL] [Abstract][Full Text] [Related]
9. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
Verbrugge SE; Assaraf YG; Dijkmans BA; Scheffer GL; Al M; den Uyl D; Oerlemans R; Chan ET; Kirk CJ; Peters GJ; van der Heijden JW; de Gruijl TD; Scheper RJ; Jansen G
J Pharmacol Exp Ther; 2012 Apr; 341(1):174-82. PubMed ID: 22235146
[TBL] [Abstract][Full Text] [Related]
10. Deacetylation induced nuclear condensation of HP1γ promotes multiple myeloma drug resistance.
Li X; Wang S; Xie Y; Jiang H; Guo J; Wang Y; Peng Z; Hu M; Wang M; Wang J; Li Q; Wang Y; Liu Z
Nat Commun; 2023 Mar; 14(1):1290. PubMed ID: 36894562
[TBL] [Abstract][Full Text] [Related]
11. Spectrum and functional validation of PSMB5 mutations in multiple myeloma.
Barrio S; Stühmer T; Da-Viá M; Barrio-Garcia C; Lehners N; Besse A; Cuenca I; Garitano-Trojaola A; Fink S; Leich E; Chatterjee M; Driessen C; Martinez-Lopez J; Rosenwald A; Beckmann R; Bargou RC; Braggio E; Stewart AK; Raab MS; Einsele H; Kortüm KM
Leukemia; 2019 Feb; 33(2):447-456. PubMed ID: 30026573
[TBL] [Abstract][Full Text] [Related]
12. Exosome-Transmitted
Xu H; Han H; Song S; Yi N; Qian C; Qiu Y; Zhou W; Hong Y; Zhuang W; Li Z; Li B; Zhuang W
Clin Cancer Res; 2019 Mar; 25(6):1923-1935. PubMed ID: 30610101
[TBL] [Abstract][Full Text] [Related]
13. Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
Niewerth D; Jansen G; Riethoff LF; van Meerloo J; Kale AJ; Moore BS; Assaraf YG; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
Mol Pharmacol; 2014 Jul; 86(1):12-9. PubMed ID: 24737138
[TBL] [Abstract][Full Text] [Related]
14. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
15. Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics.
Wang L; Kumar S; Fridley BL; Kalari KR; Moon I; Pelleymounter LL; Hildebrandt MA; Batzler A; Eckloff BW; Wieben ED; Greipp PR
Clin Cancer Res; 2008 Jun; 14(11):3503-13. PubMed ID: 18519783
[TBL] [Abstract][Full Text] [Related]
16. Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.
Yu Z; Wei X; Liu L; Sun H; Fang T; Wang L; Li Y; Sui W; Wang K; He Y; Zhao Y; Huang W; An G; Meng F; Huang C; Yu T; Anderson KC; Cheng T; Qiu L; Hao M
EBioMedicine; 2022 Apr; 78():103950. PubMed ID: 35344764
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
[TBL] [Abstract][Full Text] [Related]
18. Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity.
Shi CX; Zhu YX; Bruins LA; Bonolo de Campos C; Stewart W; Braggio E; Stewart AK
Mol Cancer Res; 2020 Oct; 18(10):1453-1464. PubMed ID: 32561655
[TBL] [Abstract][Full Text] [Related]
19. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
[No Abstract] [Full Text] [Related]
20. A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment.
Chroma K; Skrott Z; Gursky J; Bacovsky J; Moudry P; Buchtova T; Mistrik M; Bartek J
Cell Death Dis; 2022 Mar; 13(3):203. PubMed ID: 35246527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
